Close Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

DCI Partners

Investor type Venture Capital

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 11
Average round size
info
The average size of a deal this fund participated in
$12M
Portfolio companies 9
Rounds per year 1.38
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.18
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Product Research
  • Health Diagnostics
  • Clinical Trials

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of DCI Partners:
Typical Co-investors
DCI Partners is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after DCI Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
10X Venture Partners Merrimack, New Hampshire, United States
Anhuisheng Renhua Qiye Guanli Zixun Youxian Gongsi Anhui, China, Hefei
CFB Croissance & Innovation Bourgogne, Dijon, France
EG Capital Advisors England, London, United Kingdom
Famous City Development Venture Capital -
Furthermore -
Kotak Life Insurance -
Mineworkers Investment Gauteng, Johannesburg, South Africa
Norma Investment England, London, United Kingdom
Northwell Ventures New Hyde Park, New York, United States
Proton Enterprises New York, New York, United States
Soochow Asset Management Co. -
Southwestern Ontario Development Fund -
Sumitomo Corporation Equity Asia China, Hong Kong, Hong Kong Island
Tensor Ventures Czech Republic, Prague, Prague
TFTR Investment China, Hubei, Wuhan
The Accelerator Group Illinois, United States, Virginia
Wings for Life -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

LUCA Science

Biotechnology
Health Care
Pharmaceutical
$35M06 Jun 2022 Chiyoda, Japan

Elixiron Immunotherapeutics

Biotechnology
$27M23 Aug 2021 New Taipei, Taiwan

Renascience

Clinical Trials
Health Care
Health Diagnostics
$455K11 Mar 2019 Chiyoda

JUNTEN BIO

Biotechnology
Product Research
$10M17 Dec 2018 Chiyoda, Japan

StemRIM

Biotechnology
Energy
Medical
Oil and Gas
Product Research
$6M07 Dec 2018 Osaka, Osaka Prefecture, Japan

Noile-Immune Biotech

Biotechnology
$546K31 May 2018 Chiyoda, Japan

Renascience

Clinical Trials
Health Care
Health Diagnostics
$6M28 Feb 2018 Japan, Chiyoda

APRINOIA Therapeutics

Biotechnology
Health Care
Health Diagnostics
Therapeutics
$11M16 Jan 2018 New Taipei

Momotaro-Gene

App Discovery
Contact Management
$10M15 Mar 2017 Japan, Okayama Prefecture
News
Elixiron Immunotherapeutics Closes $27M Series A-1 Financing Round

– Elixiron Immunotherapeutics from San Francisco develops therapeutics for cancer, neurological diseases and inflammatory disorders.
– The company closed a $27m Series A-1 extension financing round.
– The round was jointly led by Pangu Capital (a new investor) and Taiwania Capital (an existing investor) and was joined by further new investors, including DCI Partners of Daiwa Securities Group, Mega International Commercial Bank, Fubon Financial Holdings and Hong Tai Electric Industrial, as well as other existing investors such as China Development Capital Industrial Bank (CDIB) Capital Group.
– The company intends to use the funds to advance phase 1 trials of two pipeline candidates and take three immuno-oncology assets towards IND applications.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent DCI Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: